Online Program Home
My Program

Abstract Details

Activity Number: 174 - Biomarkers and Endpoint Validation
Type: Contributed
Date/Time: Monday, July 30, 2018 : 10:30 AM to 12:20 PM
Sponsor: Biopharmaceutical Section
Abstract #330150 Presentation
Title: Leveraging Omics Biomarker in Early Clinical Trials - Concept, Utility and Impact on Decision Making
Author(s): Weidong Zhang*
Companies: Pfizer Inc.
Keywords: biomarker; omics; clinical trial; proof of mechanism

Biomarkers are becoming an indispensable addition to clinical development. Modern biotechnologies such as omics have brought unprecedented opportunities for biomarker discovery and applying the knowledge of biomarkers in clinical trials. However, significant challenges remain in many areas including statistical modeling.

In this presentation, the concept of biomarkers and their roles in drug discovery will be briefly reviewed. The presentation will focus on statistical issues and advancement on the utility of the biomarkers and their impact on early clinical trials such as proof of mechanism (POM). Specifically, biomarker strategies in early clinical trial decision making using omics data, e.g. quantification of pharmacological effect, correlative analysis between biomarker and clinical endpoints and relevant statistical challenges, will be discussed. Case studies will be presented.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2018 program